Alpha 2.0
Login Register
» Authors » Paula Ypma

Paula Ypma

Explore the profile of Paula Ypma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 221
Followers 0
Related Specialties
Hematology
Oncology
Cardiology & Vascular Diseases
Top 10 Co-Authors
Sonja Zweegman
Pieter Sonneveld
Ab A Aaldriks
Laurens Nieuwenhuizen
Saskia le Cessie
Bea C Tanis
Britta A P Laros-van Gorkom
Karin Fijnvandraat
Bronno van der Holt
Sandra Croockewit
Published In
Lancet Haematol
Acta Oncol
Hemasphere
Br J Haematol
Haemophilia
Affiliations
Soon will be listed here.
Recent Articles
1.
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
Mai E, Nogai A, Lokhorst H, van der Holt B, Zweegman S, Weisel K, et al.
Hemasphere . 2024 Nov; 8(11):e70052. PMID: 39569355
No abstract available.
2.
Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity
de Jonge N, Janssen J, Ypma P, Herbers A, de Kreuk A, Vasmel W, et al.
Support Care Cancer . 2024 Aug; 32(9):579. PMID: 39115709
Purpose: Haematology patients with high-risk neutropenia are prone to mucosal-barrier injury-associated laboratory-confirmed bloodstream infections (MBI-LCBI). We assessed risk factors for MBI-LCBI including candidaemia in neutropenic haematology patients with fever. Methods:...
3.
Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study
Brands M, Janssen E, Cnossen M, Smit C, van Vulpen L, Van der Valk P, et al.
Haemophilia . 2023 Aug; 29(5):1191-1201. PMID: 37602825
Introduction: Care for adolescents with haemophilia is transferred from paediatric to adult care around the age of 18 years. Transition programs help to prepare adolescents for this transfer and prevent...
4.
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, et al.
Hemasphere . 2022 Oct; 6(10):e786. PMID: 36204691
This phase 2 trial investigated reinduction with carfilzomib, pomalidomide, and dexamethasone (KPd) and continuous pomalidomide/dexamethasone in patients at first progression during lenalidomide maintenance. The second objective was to evaluate high-dose...
5.
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
de Jonge N, Sikkens J, Zweegman S, Beeker A, Ypma P, Herbers A, et al.
Lancet Haematol . 2022 Jun; 9(8):e563-e572. PMID: 35691326
Background: Early antibiotic discontinuation has been advocated in haematology patients with fever of unknown origin during chemotherapy-induced neutropenia, but its safety is unknown. We aimed to assess if short treatment...
6.
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
van Moort I, Preijers T, Bukkems L, Hazendonk H, van der Bom J, Laros-van Gorkom B, et al.
Lancet Haematol . 2021 Jun; 8(7):e492-e502. PMID: 34171280
Background: Dosing of replacement therapy with factor VIII concentrate in patients with haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of factor VIII concentrate should be avoided...
7.
von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients
van Moort I, Bukkems L, Heijdra J, Schutgens R, Laros-van Gorkom B, Nieuwenhuizen L, et al.
Thromb Haemost . 2020 Jun; 120(7):1056-1065. PMID: 32480417
Background:  von Willebrand factor (VWF) is crucial for optimal dosing of factor VIII (FVIII) concentrate in hemophilia A patients as it protects FVIII from premature clearance. To date, it is...
8.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):...
Cavo M, Gay F, Beksac M, Pantani L, Petrucci M, Dimopoulos M, et al.
Lancet Haematol . 2020 May; 7(6):e456-e468. PMID: 32359506
Background: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma....
9.
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
van de Donk N, van der Holt B, Minnema M, Vellenga E, Croockewit S, Kersten M, et al.
Lancet Haematol . 2018 Oct; 5(10):e479-e492. PMID: 30290905
Background: In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous...
10.
Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly
Aaldriks A, Maartense E, Nortier H, van der Geest L, le Cessie S, Tanis B, et al.
Acta Oncol . 2015 Aug; 55(1):15-23. PMID: 26305809
Background: Comprehensive geriatric assessment (CGA) is a multidimensional method to detect frailty in elderly patients. Time saving could be accomplished by identifying those individual items that classify elderly cancer patients...